Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease, and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in elderly patients. Although increasingly detected, a number of aspects including the pathophysiology, the clinical and neuroradiological phenotype, and the disease course are still under investigation. The incomplete knowledge of the disease limits the implementation of evidence-based guidelines on patient’s clinical management and the development of treatments able to prevent or reduce disease progression. The SENECA (SEarchiNg biomarkErs of Cerebral Angiopathy) project is the first Italian multicenter cohort study aimed at better defining the disease natural history and identifying clinical and neuroradiological markers of disease progression. By a multidisciplinary approach and the collection of a large and well-phenotyped series and biorepository of CAA patients, the study is ultimately expected to improve the diagnosis and the knowledge of CAA pathophysiological mechanisms.

Original languageEnglish
JournalNeurological Sciences
Publication statusAccepted/In press - Jan 1 2020


  • Biomarkers
  • Cerebral amyloid angiopathy
  • Cortical superficial siderosis
  • Dementia
  • Intracerebral hemorrhage
  • Microbleeds
  • Neuroimaging
  • Small vessel disease

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project'. Together they form a unique fingerprint.

Cite this